Selected article for: "necrosis factor and tumor necrosis factor"
Author: Mathilde ROUMIER; Romain PAULE; Matthieu GROH; Alexandre VALLEE; Felix ACKERMANN
Title: Interleukin-6 blockade for severe COVID-19
  • Document date: 2020_4_22
    • ID: 0ou5f158_2
    Snippet: Notwithstanding the shortcomings of this retrospective small sample-size study, we believe that these preliminary findings support the fostering of research efforts in the fight against COVID-19-induced inflammation, especially before patients require admission to the ICU. there is growing evidence that virally-induced pro-inflammatory cytokines (including Interleukin (IL)1β, IL-6, tumor necrosis factor-α, and granulocyte colony stimulating fac.....
    Document: Notwithstanding the shortcomings of this retrospective small sample-size study, we believe that these preliminary findings support the fostering of research efforts in the fight against COVID-19-induced inflammation, especially before patients require admission to the ICU. there is growing evidence that virally-induced pro-inflammatory cytokines (including Interleukin (IL)1β, IL-6, tumor necrosis factor-α, and granulocyte colony stimulating factor) lead to both hyperinflammatory and procoagulatory states at a late-stage of the disease (1, 2) . Such findings are further corroborated by recent studies, which highlighted that high levels of C-reactive protein, IL-6 and D-Dimer upon admission were predictors of mortality (3, 4) . In their recent Comment, Mehta and colleagues exhorted physicians to screen patients with severe COVID-19 for hyperinflammation and suggested that immunosuppressive and/or immunomodulatory drugs should be investigated in this setting (5) . Here, we relate our short-term -yet promising -experience regarding IL6 blockade for severe COVID-19 with tocilizumab.

    Search related documents:
    Co phrase search for related documents
    • admission dimer and high level: 1, 2, 3, 4, 5, 6, 7
    • admission dimer and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
    • admission dimer and necrosis factor: 1
    • admission dimer and sample size: 1, 2, 3, 4, 5, 6, 7
    • admission dimer and sample size study: 1, 2
    • admission dimer and small sample size study: 1, 2
    • admission dimer and tumor necrosis factor: 1